Tyroka Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Pazopanib

Indications/Uses

1st-line treatment of advanced renal cell carcinoma (RCC) in adults & for patients who have received prior cytokine therapy for advanced disease. Adult patients w/ selective subtypes of soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed w/in 12 mth after (neo) adjuvant therapy.

Dosage/Direction for Use

Adult RCC & STS 800 mg once daily. May reduce initial dose to 400 mg daily, subsequent dose modification should be in 200 mg decrements or increments based on individual tolerability. Max daily dose: 800 mg. Patient w/ mild abnormalities in serum liver tests 800 mg once daily. Moderate hepatic impairment Reduce dose to 200 mg once daily.

Administration

Should be taken on an empty stomach: Take at least 1 hr before or 2 hr after meals. Swallow whole w/ water, do not break/crush.

Contraindications

Hypersensitivity. Severe hepatic impairment.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01EX03 - pazopanib ; Belongs to the class of other protein kinase inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Tyroka FC tab 200 mg

Packing/Price

1's

Tyroka

pazopanib

Manufacturer:

Lotus Pharmaceutical